Used in pharmaceutical research as a proteolysis targeting chimera (PROTAC) linker component, enabling targeted protein degradation. Its structure facilitates the connection between an E3 ligase binder and a target protein ligand, promoting ubiquitination and subsequent degradation of disease-related proteins. This compound is particularly valuable in developing therapies for cancer and neurodegenerative diseases by selectively removing pathogenic proteins from cells. It is also employed in biochemical assays to study protein function and validate drug targets.